The integration of herbal medicine into modern medical practices including cancer treatments must take into account the interrelated issues of quality, safety, and efficacy. Quality is the paramount issue because it can affect the efficacy and/or safety of the herbal products being used. Current product quality ranges from very high to very low due to intrinsic, extrinsic, and regulatory factors. Intrinsically, species differences, organ specificity, diurnal and seasonal variations can affect the qualitative and quantitative accumulation of active chemical constituents in the source medicinal plants. Extrinsically, environmental factors; field collection methods such as cultivation, harvest, post-harvest transport and storage; manufacturing practices; inadvertent contamination and substitution; and intentional adulteration are contributing factors to the quality of herbal medicinal products. Source plant materials that are contaminated with microbes, microbial toxins, environmental pollutants, or heavy metals; or finished products that are adulterated with foreign toxic plants or synthetic pharmaceutical agents can lead to adverse events. Substandard source materials or finished products will yield therapeutically less effective agents. Herbal medicine quality can also be attributed to regulatory practices. In a number of countries, herbal medicines are unregulated, which has led to product quality differences. Product quality improvement may be achieved by implementing control measures from the point of medicinal plant procurement under good agricultural practices (GAPs) and the manufacture of the finished botanical products under good manufacturing practices (GMPs), plus postmarketing quality assurance surveillance. The lack of pharmacological and clinical data on the majority of herbal medicinal products is a major impediment to the integration of herbal medicines into conventional medical practices. For valid integration, pharmacological and especially, clinical studies, must be conducted on those plants lacking such data. Adverse events, including drug-herb interaction must also be monitored to promote a safe integration of efficacious herbal medicine into conventional medical practices.
Traditional medicine (TRM) has been defined as the sum total of the knowledge, skills, and practices based on the theories, beliefs, and experiences indigenous to different cultures, whether explicable or not, used in the maintenance of health, as well as in the prevention, diagnosis, improvement, or treatment of physical and mental illness. 1 According to a 1983 World Health Organization (WHO) estimate, a majority of the population in developing countries depend on traditional and herbal medicines as their primary source of health care. 2 Over the past decade, there has been an increased global interest in traditional systems of medicine and herbal medicinal products not only in response to the health care needs of developing countries, where access to modern medicine is rare or nonexistent, but also in affluent nations, where the use of herbal medicines and acupuncture is now readily accepted by large segments of the population. In developed countries, nonconventional medical modalities, also designated as complementary and alternative medicine (CAM), are often used concomitantly with conventional medicine in medical treatments, including cancer therapy. The popularity of CAM in the USA is reflected in a survey, which showed its use increased from 34% in 1990 to 42% of adults in 1997. 3 The same survey showed that the American consumers spent $27 billion on alternative treatments, and an estimated $5.1 billion on herbal medicines in 1997. 3 In the same year, the global market for herbal products was estimated to be approximately $20 billion. 4, 5 With the increased and widespread use of multiple medical modalities in recent years, coupled with the need to provide health care to all the people in both the developing and developed countries, there arose a new modality known as integrated or integrative medicine. Integrated medicine has been defined as practicing medicine in a way that selectively incorporates elements of CAM into comprehensive treatment plans alongside orthodox methods of diagnosis and treatment. 6, 7 It can also mean the incorporation of TRM into the general health service systems, in which both orthodox and traditional systems of medical practices are recognized. 7 In developed countries such as the United States of America, integrative medicine is meant to be the former. The rational integration of herbal medicine into modern medical practices, including cancer therapy, should be accomplished on a scientific basis, taking into account the interrelated issues of quality, safety, and efficacy.
Quality
A current impediment to the integration of herbal medicines into modern medical practices is the quality of these products, which can affect their efficacy and/or safety. Herbal product quality ranges from very high to very low. A recent study on selected commercial ginseng products prepared from Panax ginseng CA Meyer and P. quinquefolius L. (Araliaceae) and eleuthero, Eleutherococcus senticosus Maxim (Araliaceae), marketed as botanical supplements in North America in the 1995-1998 period, showed that the ginsenoside contents of 232 Panax ginseng and 81 Panax quinquefolius products ranged from 0.00 to 13.54% and 0.009% to 8.00%, respectively, and that approximately 26% of these products did not meet label claims. 8, 9 The eleutherosides B and E content of eleuthero root powder and other formulated extract products also showed large variation. 8, 9 Studies on the quality of St. John's wort (Hypericum perforatum L. [Hypericaceae]) products showed hypericin content ranging from 22% to 140% of label claim, when analyzed using an official spectrophotometric procedure, 10 and from 47% to 165% employing an HPLC method. 11 Similarly, silymarin from milk thistle (Silybum marianum [L.] Gaertn [Asteraceae]) was detected at 58% to 116% of the label claim. 12 Aside from the variation in the chemical content of herbal medicine, there can also be pharmaceutical quality differences in these products. In an in vitro dissolution and bioequivalent study of 9 silymarin products, 3 yielded 100%, 50%, and 0% of silymarin after 1 hour under official dissolution study conditions. 12 A bioequivalency study of 3 of these products showed that the bioavailability of 1 product was 2fold greater than the other 2 preparations. 12 Botanicals and botanical product quality and quality variations are due to a number of factors, ranging from intrinsic and extrinsic influences to regulatory practices.
Intrinsic and Extrinsic Factors
It is well established that intrinsic and extrinsic factors including species differences, organ specificity, diurnal and seasonal variation, environment, field collection and cultivation methods, contamination, substitution, adulteration, and processing and manufacturing practices greatly affect botanical quality. [13] [14] [15] [16] [17] Intrinsically, botanicals are derived from dynamic living organisms, each of which is capable of being slightly different in its physical and chemical characters due to genetic in-fluence. This phenomenon has been well documented. A case in point concerns the accumulation of hypericin in Hypericum perforatum (St. John's wort [SJW]), which showed that narrow leafed populations have greater concentrations than the broader leafed variety although the direct therapeutic significance of this particular variation is unclear, as hypericin, although pharmacologically active, is not considered a significant pharmacologic agent in the antidepressive use of SJW; the primary reason many commercial extracts are standardized to hypericin content is that the hypericin acts as a "marker compound" for the purposes of quality control. 18, 19 In general, both qualitative and quantitative variations of phytochemicals are greater in wild than in domesticated populations of the same species. Recent studies on the content of artemisinin, an antimalarial agent in Artemisia annua L. (Asteraceae) 14 ; on michellamine B, a compound with in vitro anti-HIV activity, in Ancistrocladus korupensis DW Thomas & RE Gereau (Ancistrocladaceae) 14 ; and on the essential oil composition of Ocimum basilicum L. (Lamiaceae) 14 showed greater content variations in the wild than in cultivated populations. Also, the secondary chemical constituents of medicinal plants differ from species to species as demonstrated by the presence of structurally different alkylamides in the roots of Echinacea angustifolia D.C., and E. purpurea (L.) Moench. (Asteraceae), and by their total absence in E. pallida (Nutt.) Nutt. 20, 21 Thus, to insure chemical uniformity, it is necessary that the starting plant material for the manufacture of botanicals be accurately identified and authenticated by their scientific names (Latin binomial). The use of common names is inadequate as they often refer to more than 1 species.
In regard to plant organ specificity, the site of biosynthesis and the site of accumulation and storage are normally different. Chemical biosynthesis usually takes place in the leaves, and phytochemicals are then transported through the stems to the roots for storage, with the chemical profiles in these organs being different from each other. Accumulation and storage can also take place in the leaves, but to a much lower extent, and very infrequently in the stems. An example of site-specific accumulation, as well as species specificity, is that of the compounds considered responsible for the immunostimulant effect of Echinacea species. These compounds encompass 5 groups of chemicals: caffeic acid derivatives, alkylamides, polyacetylenes (ketodialkenes and ketodialkynes), glycoproteins and polysaccharides. As indicated above, alkylamides are found in the roots of Echinacea angustifolia and E. purpurea, but they are structurally different and are totally absent in E. pallida roots. Polyacetylenes, on the other hand, are present abundantly in the roots of E. pallida, but absent in E. angustifolia and E. purpurea roots. Although the glycoproteins and polysaccharides are present in the fresh juices and aerial parts of all 3 species, they occur only in minute quantities in the roots. 20, 21 Diurnal and seasonal variations are other intrinsic factors affecting chemical accumulation in both wild and cultivated plants. Depending on the plant, the accumulation of chemical constituents can occur at any time during the various stages of their growth. In a majority of cases, maximum chemical accumulation occurs at the time of flowering, followed by a decline beginning at the fruiting stage. The time of harvest or field collection can thus influence the quality of the final herbal product. 22, 23 There are many extrinsic factors affecting qualities of medicinal plants. It has been well established that factors such as soil, light, water, temperature, and nutrients can, and do, affect phytochemical accumulation in plants, as exemplified by alkaloid concentrations of 1.3% and 0.3%, respectively, in Atropa belladonna L. (Solanaceae) grown in the Caucasus and those cultivated in Sweden 15 ; essential oil content in shade-grown (1.09%) and normal light-grown (1.43%) Mentha x piperita L. (Lamiaceae) plants 15 ; and by the silymarin content being highest in the fruits of plants grown under 60% water/field capacity (1.39%) and nitrogen level of 100 kg (1.46%) and 150 kg (1.42%) per feddan. 24 The methods employed in the field collection from the wild, as well as in commercial cultivation, harvest, post-harvest processing, shipping and storage can also influence the physical appearance and chemical quality of the botanical source materials. Contamination by microbial and chemical agents (pesticides, herbicides, heavy metals), as well as by insect, animal, animal parts, and animal excreta during any of the stages of source plant material production can lead to lower quality and/or unsafe materials. [14] [15] [16] [17] Botanicals collected in the wild often include nontargeted species either by accidental substitution or by intentional adulteration. However, adulteration and/or substitution of cultivated botanicals have also been documented. Substitution of Periploca sepium Bunge (Asclepiadaceae) for eleuthero (Eleutherococcus senticosus) has been widely documented and is regarded as responsible for the "hairy baby" case involving maternal/neonatal androgenization. 25 25 Adulteration of herbal medicine with synthetic drugs represents another problem in product quality. Foremost among these herbal mixtures are multicomponent Chinese or Ayurvedic herbal remedies. Chemical analysis of some arthritis remedies have led to the finding that synthetic anti-inflammatory drugs such as phenylbutazone, indomethacin and/or corticoid steroids have been added. 27 In a recent study of chemical adulteration of traditional medicine in Taiwan, 23.7 % (618 of 2609) of samples collected by 8 major hospitals were found to contain 1 or more synthetic therapeutic agents, including caffeine, acetaminophen, indomethacin, hydrochlorothiazide, prednisolone, ethoxybenzamide, phenylbutazone, betamethasone, theophylline, dexamethasone, diazepam, bucetin, chlorpheniramine maleate, prednisone, oxyphenbutazone, diclofenac sodium, ibuprofen, cortisone, ketoprofen, phenobarbital, hydrocortisone acetate, niflumic acid, triamcinolone, diethylpropion, mefenamic acid, prioxicam, and salicylamide. 28 The most frequent adulterants were caffeine, acetaminophen, indomethacin, hydrochlorothiazide, prednislone, and chlorzoxazone in 213, 167, 152, 127, 91, and 87 cases, respectively.
Heavy metal contamination can occur at the cultivation, post-harvest treatment, or product manufacturing stages. Lead and thallium contamination has been reported in multicomponent herbal mixtures. 27, 29 Besides the unintentional in-process adulteration, it is well established that Ayurvedic and traditional Chinese medicine sometimes employ complex mixtures of plant, animal, and mineral substances, including heavy metals. It is not uncommon to find appreciable quantities of heavy metals such as lead, mercury, cadmium, arsenic, and gold in certain formulations. Cases of lead, thallium, mercury, arsenic, gold, and cadmium poisoning from the consumption of such products have been documented. 27, 29 
Regulatory Influence
Botanical product quality can also be influenced by regulatory status, which varies from country to country. 30 In the European community, herbal medicines are regulated as medicine and subject to mandated standards, whereas in the United States, very few botanical products are available as prescription or overthe-counter (OTC) drugs. The majority of botanicals are marketed in the United States as dietary supplements under the provisions of the Dietary Supplement Health and Education Act (DSHEA) of 1994. By law, strict good manufacturing practices (GMPs) are re-quired in the production of prescription and OTC drugs; regulatory provisions under DSHEA provide little assurance of identity, quality or purity for botanical dietary supplements, which are manufactured according to requirements for conventional food products (DSHEA stipulates that supplements are food and not drugs). Thus, botanical dietary supplement products have not yet been subjected to mandated quality assurance (QA)/quality control (QC) standards as in the case of prescription and OTC drugs. 31 New GMPs are under development by the FDA that will help ensure a higher standard of GMP for supplements than for food. Elsewhere in the world, national policies exist in most of Asia and Southeast Asia. In some countries, these products are totally unregulated. Consequently, product quality may differ from country to country, and within the same country, from product brand to product brand, and even from lot to lot within the same brand.
QA and QC
For effective integration of herbal medicine into modern therapeutic practices, the quality of botanicals must be assured by control measures taken from the point of medicinal plant procurement, whether by field collection from the wild or by cultivation, under good agricultural practice (GAP) conditions, 32 because the quality of the finished botanical products is obviously directly related to the quality of the raw materials. Whether field collected or produced by cultivation, authentication of plant species by a taxonomic botanist is paramount to insure that the correct source material is acquired. It is essential that the plant materials are identified by their binomial Latin names, and a description of the macroscopic, microscopic, and organoleptic (sensory) characters be provided along with herbarium specimens, drawings or photographs. 13, [33] [34] [35] [36] In the field collection of medicinal plants, care must be exercised to avoid the acquisition of nontargeted species, and to free the targeted source material of undesirable plant parts, soil, rock, insects, animals, animal excreta, and other contaminants. Post-collection treatments should mirror those accorded cultivated plant materials. Due to their genetic and chemical content variations, the site and date should be recorded for each collection. The production of raw materials by cultivation should normally lead to more uniform botanical products due to greater genetic uniformity. The production of quality raw materials can only be assured by employing GAPs such as those carried out in the commercial cultivation of Ginkgo biloba L. (Ginkgoaceae) 37 and of Echinacea species. 38 The harvested source materials must be processed to produce the finished products under GMPs. The World Health Organization has published general guidelines for the GMP production of botanical products. 39 GMP procedures employed for the manufacture of botanical products involve, at the raw material production end, botanical taxonomic identification to assure species identification; at the processing and manufacturing stage, macroscopic, microscopic, organoleptic analysis and analytical procedures similar to those employed for the manufacture of conventional drugs to assure quality and purity by appropriate protocols. 13, 35, 39 Post-marketing quality assurance surveillance by regulatory agencies will ensure the marketing of quality products for use in integrative medicine.
Safety
Herbal medicines are generally safe when properly used at normal therapeutic doses. Adverse effects consist primarily of mild and infrequent gastrointestinal or dermatological reactions. 40 A study monitoring the adverse effects of thousands of users of ginkgo, St. John's wort, and kava showed that less than 3% of patients encountered mild side effects. 12 Digitalis species, Rauvolfia serpentina (L.) Benth. ex Kurz., (Apocynaceae) Atropa belladonna, and Strychnos nux vomica L. (Strychnaceae), among others, are toxic plants that are useful therapeutic agents that can be employed safely when administered in proper doses. On the other hand, there are medicinal plants that persistently evoke moderate to severe reactions, and should not be employed in any medical therapy. Plants including species of Senecio, Crotalaria, and Symphytum, which contain pyrrolizidine alkaloids having an unsaturated 1,2-double bond in the pyrrolizidine ring, should be avoided due to the hepatotoxic effect of these compounds. On the other hand, Echinacea species that contain non-hepatotoxic saturated pyrrolizidine alkaloids are safe for consumption. 41 Aristolochia species are another example of plants containing toxic chemical constituents that should not be used medically. Aristolochic acid I, found in all species of Aristochia investigated to-date, has been identified as a potent carcinogen and nephrotoxin. [42] [43] [44] Renal failures, nephritis, and urinary tract neoplasm have been associated with use of Chinese and Kampo herbal medicine preparations that contain Aristolochia species. [44] [45] [46] [47] In recent years, it has become increasing apparent that even therapeutically safe herbs can manifest toxic effects as a result of herb-drug interaction, when administered concomitantly with synthetic pharmaceutical agents. For example, St. John's wort (Hypericum perforatum), an effective botanical used in the management of mild to moderate depression, has been found to increase the effects of MAO inhibitors or serotonin re-uptake inhibitors; reduce the blood levels, hence the pharmacological effects, of anticonvulsants (carbamazepine, phenobarbitone), anticoagulants (warfarin, phenprocoumon), oral contraceptives, theophylline, digoxin, cyclosporin, HIV reverse transcriptase inhibitors (nevirapine, efavirenz), and protease inhibitors (indinavir); increase photosensitivity when given with other photosensitizing drugs; and prolong narcotic-induced sleeping time. [48] [49] [50] [51] [52] [53] [54] [55] Such interactions must be considered when evaluating herbal preparations for integration into modern medical practices. Although by no means comprehensive, a series of recent reference books on popular medicinal plants have begun to address this issue. 31, [56] [57] [58] In addition to the toxic effects/interactions of intrinsic chemical constituents, adulteration of herbal medicine with synthetic drugs or contamination with heavy metals and microbes (see above) affect the safety of these products in therapy. Avoidance of these products in integrative medicine is recommended.
Where safety information is lacking on any medicinal plants being contemplated for integrative medicine use, relevant research must be performed prior to its employment. The WHO has established guidelines for such studies. 59 Adverse events, including drug-herb interaction must also be monitored to promote a safe integration of efficacious herbal medicine into conventional medical practices.
Efficacy
It has been estimated that currently more than 1500 herbal products are available in the US market alone 60 with little or no scientific documentation of either their safety or efficacy. For a valid scientific-based integration, pharmacological and clinical studies, especially, must be conducted on those plants lacking such data. Current clinical studies on herbal medicine have been carried out under a variety of conditions, including single case, open, blind, double blind, randomized, and cross-over studies. Ideally, all clinical studies should be conducted by the double-blind, randomized, cross-over method. However, this may not be feasible for a variety of reasons. Nevertheless, the most suitable method for a given herbal medicine should be used to assess its efficacy to validate its usefulness as an integrated therapeutic agent. In recent years, the effectiveness of a number of herbal medicines have been clinically validated, including garlic bulb [Allium sativum L. (Liliaceae) 56, 57 Such clinical validations represent a most important step in the scientific integration of herbal preparations into modern therapy. Unfortunately, these represent but a minuscule proportion of the number of evidence based studies needed for the clinician to use in integrative medicine. In order to answer the questions of "does it work?", "how does it work?", "is it safe?", "will it interact with conventional pharmaceuticals?", in vivo pharmacological and clinical studies must be accorded to as many botanical products as possible. Such studies have been the subjects of much discussion, [61] [62] [63] [64] and the WHO has published a number of guidelines for pharmacological and clinical evaluation of herbal and traditional medicine. 1, 33, 34, 59, 60 In clinical studies, be they open, single blind, double blind, randomized, or crossover, the clinician must be aware that standards of quality for botanical products do not exist in many countries, including the United States. Therefore, the products being evaluated must be accurately defined and the sources identified. 64 Otherwise, the data being published will be invalid and/or misleading.
Conclusion/Prospect
There is a current movement for the scientific integration of herbal medicine into modern medical practices. Associated with this integrative herbal medicine are the interrelated issues of quality, safety, and efficacy. The present lack of uniform quality in herbal products is an impediment, as both safety (toxicity) and efficacy will vary from product to product and from batch to batch. Fortunately, quality control methods do exist for the GAP and GMP production of botanical products, and there is a growing awareness and acceptance by the herbal product industry of the absolute need for standardization of botanical extracts to ensure batch-to-batch consistency. There are also available a number of research guidelines on the chemical, biological, and clinical research on herbal medicine from the WHO. When safety and efficacy are established through valid scientific and clinical research, the integration of herbal medicine into cancer therapy and other orthodox medical practices will be fully accepted.
